ArticleScientific reports2025
TRAIL-resistant glioma cells resist Withania somnifera mediated apoptosis via USP5 upregulation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- USP5 in cancer: a therapeutic window into metabolism and drug resistance.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The tumor necrosis factor related apoptosis inducing ligand (TRAIL) shows a potential therapeutic by inducing apoptosis in glioma cells and sparing normal cells, but TRAIL resistance and chemotherapeutic resistance still prevails in glioma and hinder its apoptotic effect. To address TRAIL resistance, we investigated the potential of Withania somnifera, a medicinal herb with recognized anti-cancer properties. The response against the therapeutic approaches led glioma to get regress but relapse is a major challenge. The study aims to evaluate the biological effect of the W. somnifera fruit extract in TRAIL resistant glioma cell lines (U87MG, LN229) and TRAIL sensitive (T98G) glioma cell lines. MTT cell viability assay were performed to assess the effect of W. somnifera fruit extract. Fluorophore conjugated Annexin V APC -PI staining was performed to study the apoptotic effect of an extract obtained from W. somnifera. The underlying mechanism comprises of USP5 mediated DR5 regulation in cell survival and its subsequent knock down led to apoptosis enhancement. The apoptotic relevant proteins SMAC, and semi quantitative PCR analyzed abundance of DR4 & DR5 receptor was quantitated. Therefore, the expression of USP5 was analyzed across 592 glioma tumor data and was correlated with the abundance of EGFR, the data was accessed from cBioportal (https://www.cbioportal.org/). Our study findings proposed the leading upregulation of deubiquitinating enzyme USP5 in TRAIL resistant U87MG and LN229 glioma cells upon treatment with Withania somnifera fruit extract promotes cell survival. Furthermore, depletion of USP5 followed with Withania somnifera fruit extract-treatment, upregulates TRAIL receptor (DR5) and SMAC protein led to apoptosis activation, reveals a survival promoting characteristic of Withania somnifera fruit extract in TRAIL resistant U87 MG and LN229 glioma cells. Furthermore, being USP5 a key promoter in tumorigenesis but is found overexpressed/mutated in 3% of glioma tumor. The leading upregulation of USP5 found interesting in our treatment set to correlate with the EGFR abundance across the tumor samples. Since, EGFR is overexpressed in 47% tumor and acquiring the potential chemo-resistant pathway led to USP5 upregulation may be detrimental causing recurrent tumor. Therefore, from our studies USP5 deubiquitinating enzyme plays a key role in latent survival. Deubiquitinating enzyme family protein USP5 upregulation and stability of apoptotic protein SMAC are found important indicator in balancing the TRAIL resistance glioma to opt unidirectional pathway which is not aberrant but rewired on W. somnifera FE treatment. Therefore, knockdown of USP5 make cells sensitive to undergo direct apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.